NZ527972A - Methods for delivering nucleic acid molecules into cells and assessment thereof - Google Patents

Methods for delivering nucleic acid molecules into cells and assessment thereof

Info

Publication number
NZ527972A
NZ527972A NZ527972A NZ52797202A NZ527972A NZ 527972 A NZ527972 A NZ 527972A NZ 527972 A NZ527972 A NZ 527972A NZ 52797202 A NZ52797202 A NZ 52797202A NZ 527972 A NZ527972 A NZ 527972A
Authority
NZ
New Zealand
Prior art keywords
cell
nucleic acid
acid molecule
cationic
cells
Prior art date
Application number
NZ527972A
Other languages
English (en)
Inventor
Gary Dejong
Sandra Louise Vanderbyl
Volker Oberle
Dirk Hoekstra
Jan Drayer
Paul Peter Tak
Original Assignee
Chromos Molecular Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/815,981 external-priority patent/US6936469B2/en
Priority claimed from US09/815,979 external-priority patent/US7294511B2/en
Priority claimed from US10/086,745 external-priority patent/US20030186390A1/en
Application filed by Chromos Molecular Systems Inc filed Critical Chromos Molecular Systems Inc
Publication of NZ527972A publication Critical patent/NZ527972A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ527972A 2001-03-22 2002-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof NZ527972A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/815,981 US6936469B2 (en) 2001-03-22 2001-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof
US09/815,979 US7294511B2 (en) 2001-03-22 2001-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof
US10/086,745 US20030186390A1 (en) 2001-03-22 2002-02-28 Methods for delivering nucleic acid molecules into cells and assessment thereof
PCT/US2002/009262 WO2002076508A1 (en) 2001-03-22 2002-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof

Publications (1)

Publication Number Publication Date
NZ527972A true NZ527972A (en) 2006-04-28

Family

ID=27375461

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ527972A NZ527972A (en) 2001-03-22 2002-03-22 Methods for delivering nucleic acid molecules into cells and assessment thereof

Country Status (6)

Country Link
EP (1) EP1383541A4 (de)
JP (1) JP2004532205A (de)
CA (1) CA2441535C (de)
IL (1) IL157703A0 (de)
NZ (1) NZ527972A (de)
WO (1) WO2002076508A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294511B2 (en) 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
NZ528003A (en) 2001-05-30 2006-09-29 Chromos Molecular Systems Inc Platform artificial chromosome expression systems (ACes) containing single or multiple site-specific recombination sites
JP4676679B2 (ja) * 2003-04-02 2011-04-27 帝人株式会社 人工軟骨
CA3079874C (en) 2004-10-22 2023-01-03 Revivicor, Inc. Ungulates with genetically modified immune systems
JP5115686B2 (ja) * 2006-04-17 2013-01-09 学校法人慶應義塾 細胞への薬剤導入装置
WO2010051288A1 (en) 2008-10-27 2010-05-06 Revivicor, Inc. Immunocompromised ungulates
EP3544497A4 (de) 2016-11-22 2020-08-05 Cedars-Sinai Medical Center Neuartiges transfektions- und wirkstofffreisetzungsvorrichtung
CN117357480B (zh) * 2023-12-08 2024-03-29 北京中科利华医药研究院有限公司 无针经皮注射用组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ253943A (en) * 1992-06-18 1997-01-29 Genpharm Int Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
NL1000884C2 (nl) * 1995-07-25 1997-01-28 Univ Groningen Transportvehikels voor macromoleculen.
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
US6074667A (en) * 1996-11-20 2000-06-13 Kinnunen; Paavo Liposomal transfection method
WO1999025385A1 (en) * 1997-11-17 1999-05-27 Imarx Pharmaceutical Corp. A method of increasing nucleic acid synthesis with ultrasound
AU785026B2 (en) * 1998-12-04 2006-08-24 Genetronics, Inc. Facs assisted methods for introducing individual chromosomes into cells

Also Published As

Publication number Publication date
WO2002076508B1 (en) 2002-12-12
EP1383541A1 (de) 2004-01-28
WO2002076508A1 (en) 2002-10-03
IL157703A0 (en) 2004-03-28
JP2004532205A (ja) 2004-10-21
EP1383541A4 (de) 2009-11-04
CA2441535A1 (en) 2002-10-03
CA2441535C (en) 2008-08-26

Similar Documents

Publication Publication Date Title
US6936469B2 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
US20060194754A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
WO2003093469A2 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
Li et al. In vivo gene transfer via intravenous administration of cationic lipid–protamine–DNA (LPD) complexes
Cervia et al. Current progress in electrotransfection as a nonviral method for gene delivery
US11332760B2 (en) Compositions and methods for genomic editing by insertion of donor polynucleotides
JP2009131276A (ja) トランス−スプライスにより生成される治療用分子
CA2134773A1 (en) Methods and compositions for in vivo gene therapy
US12018080B2 (en) Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
US6372720B1 (en) Liposome fusion and delivery vehicle
US20030186390A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
NZ527972A (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030143742A1 (en) Compositions for receptor/liposome mediated transfection and methods of using same
AU2001281911B2 (en) Method for introducing nucleic acids and other biologically active molecules into the nucleus of higher eukaryotic cells by means of an electrical current
Wong et al. Vector systems for prenatal gene therapy: principles of non-viral vector design and production
JP2002508956A (ja) 遺伝子送達のための方法および組成物
AU2005225124B2 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
WO2021041716A2 (en) Therapeutic editing to treat cardiomyopathy
CA2633522A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
AU2002306877A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
US20020106635A1 (en) Cytokine resistant cytomegalovirus promoter mutants and related products and methods
Qureshi O VSP 1998 Prospects of recombinase-mediated HPRT Gene Therapy for Lesch-Nyhan disease BERTOLOTTI, R.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed